39 articles for thisTarget
The following articles (labelled with PubMed ID or TBD) are for your review
PMID
Data
Article Title
Organization
Rickettsia prowazekii methionine aminopeptidase as a promising target for the development of antibacterial agents.
Northern Illinois University
Synthesis and antitumor activity of 1,3,4-oxadiazole possessing 1,4-benzodioxan moiety as a novel class of potent methionine aminopeptidase type II inhibitors.
Nanjing University
Pyridinylquinazolines selectively inhibit human methionine aminopeptidase-1 in cells.
Johns Hopkins University School of Medicine
QSAR study of anthranilic acid sulfonamides as inhibitors of methionine aminopeptidase-2 using LS-SVM and GRNN based on principal components.
Kermanshah University of Medical Sciences
Subtype-selectivity of metal-dependent methionine aminopeptidase inhibitors.
Universit£T Heidelberg
A selective account of effective paradigms and significant outcomes in the discovery of inspirational marine natural products.
University of California Santa Cruz
Synthesis and antitumor activity of 1,2,4-triazoles having 1,4-benzodioxan fragment as a novel class of potent methionine aminopeptidase type II inhibitors.
Nanjing University
Fumarranol, a rearranged fumagillin analogue that inhibits angiogenesis in vivo.
The Johns Hopkins University School of Medicine
Novel Antimicrobial 8-Hydroxyquinoline-Based Agents: Current Development, Structure-Activity Relationships, and Perspectives.
Universidade Federal Do Rio Grande Do Sul
Design and synthesis of beta-amino-alpha-hydroxy amide derivatives as inhibitors of MetAP2 and HUVEC growth.
Celera
3-Amino-2-hydroxyamides and related compounds as inhibitors of methionine aminopeptidase-2.
Abbott Laboratories
Peptidyl hydroxamic acids as methionine aminopeptidase inhibitors.
The Ohio State University
Fumagalone, a reversible inhibitor of type 2 methionine aminopeptidase and angiogenesis.
Johns Hopkins University School of Medicine
Discovery and Structure-Based Optimization of Next-Generation Reversible Methionine Aminopeptidase-2 (MetAP-2) Inhibitors.
Merck Healthcare
Emerging and Re-Emerging Warheads for Targeted Covalent Inhibitors: Applications in Medicinal Chemistry and Chemical Biology.
Eberhard Karls University T£Bingen
Research progress in the biological activities of 3,4,5-trimethoxycinnamic acid (TMCA) derivatives.
Northwest University
The Bengamides: A Mini-Review of Natural Sources, Analogues, Biological Properties, Biosynthetic Origins, and Future Prospects.
Colorado Mesa University
Spiroepoxytriazoles Are Fumagillin-like Irreversible Inhibitors of MetAP2 with Potent Cellular Activity.
German Cancer Research Center (Dkfz)
Regulation of c-Src nonreceptor tyrosine kinase activity by bengamide A through inhibition of methionine aminopeptidases.
The Johns Hopkins University
Methionine aminopeptidase (type 2) is the common target for angiogenesis inhibitors AGM-1470 and ovalicin.
Massachusetts Institute of Technology
Elucidation of the function of type 1 human methionine aminopeptidase during cell cycle progression.
Johns Hopkins University
Lead optimization of methionine aminopeptidase-2 (MetAP2) inhibitors containing sulfonamides of 5,6-disubstituted anthranilic acids.
Abbott Laboratories
Development of sulfonamide compounds as potent methionine aminopeptidase type II inhibitors with antiproliferative properties.
Abbott Laboratories
Tumor suppression by a rationally designed reversible inhibitor of methionine aminopeptidase-2.
Abbott Laboratories
Discovery and optimization of anthranilic acid sulfonamides as inhibitors of methionine aminopeptidase-2: a structural basis for the reduction of albumin binding.
Abbott Laboratories
4-Aryl-1,2,3-triazole: a novel template for a reversible methionine aminopeptidase 2 inhibitor, optimized to inhibit angiogenesis in vivo.
Gsk